To evaluate whether WT GXYLT1 and GXYLT1S212* enhanced cell metastasis via the MAPK pathway, we inhibited MAPK pathway activity using the ERK kinase inhibitor SCH772984 and analyzed the migration and invasion of CRC cells expressing WT GXYLT1 or GXYLT1S212*. Here, GXYLT1 is linked to colorectal carcinoma.